Search
Utidelone
go.drugbank.com/drugs/DB17575InvestigationalUtidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue produced by genetic engineering.[A257544,A257549] It is under investigation in clinical trials for various cancers.
AG0302-COVID19
go.drugbank.com/drugs/DB16435InvestigationalSponsored by Anges, Inc. in Japan, the AG0302-COVID19 is a DNA-based vaccine that recently completed Phase I/II trials (NCT04527081)[A226813, L30548].
Influenza B virus B/Massachusetts/2/2012 hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB14393ApprovedInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
go.drugbank.com/drugs/DB14394ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB14399ApprovedInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Massachusetts/2/2012 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB14400ApprovedInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB14403ApprovedInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Christchurch/16/2010 NIB-74XP (H1N1) hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14419ApprovedInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Utah/9/2014 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB14421ApprovedInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB14424ApprovedInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.